This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Combined Modality (Adjuvant) Therapy

Kenneth Cowan, MD, PhD; Marc Lippman, MD

Arch Intern Med. 1981;141(8):1055-1059.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Breast cancer remains the leading cause of death due to cancer in women. A woman living in the United States currently has a lifetime risk of one chance in 11 that breast cancer will develop. In 1980 alone, there will be more than 100,000 new cases in this country. Despite the fact that the majority of patients initially have "operable" lesions, almost half of the patients who experience tumor recurrences will relapse. Although therapy for advanced disease is successful in prolonging survival, virtually all of these women will eventually die of their disease. During the past several years, basic research has provided new insights into the biology of breast cancer that have resulted in new therapeutic approaches to this disease. In addition, the development of effective and relatively safe combination chemotherapy for metastatic disease has encouraged the earlier use of cytotoxic drugs in the treatment of breast cancer.

New hope . . . [Full Text PDF of this Article]

Author Affiliations
From the Medical Breast Cancer Section, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Accepted for publication June 23,1980.

Reprint requests to Medical Breast Cancer Section, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20205 (Dr Cowan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?